PVR and neoplasm: In vitro cytotoxicity assays revealed that CD155 CAR-T cells, but not mock T cells or CD19 CAR-T cells, effectively killed CD155+CD19– tumor cells (U937 and A549) in a dose-dependent manner (Supplemental Figure 5, A–C).